Scilex (SCLX) Stock: Buy, Sell, or Hold?
SCLX - Scilex Holding Company Common Stock
$2.56
0.03 (1.19%)
▲
5d:
-10.18%
30d:
-52.15%
90d:
-65.36%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 13, 2026
21d
Get Alerted When SCLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SCLX is down 10.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SCLX is down 10.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.16
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.45
42.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SCLX is currently trading at $2.56, which is considered oversold relative to its 30-day fair value range of $2.98 to $5.01. From a valuation perspective, the stock is trading at a discount (Forward PE: 3.5) compared to its historical average (7.0). Remarkably, the market is currently pricing in an annual earnings decline of 20.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SCLX is in a strong downtrend. The price is currently testing key support at $2.51. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $490.00 (+19040.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SCLX is in a strong downtrend. The price is currently testing key support at $2.51. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $490.00 (+19040.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.98 -
$5.01
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 19040.6% below Wall St target ($490.00)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.98 -
$5.01
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.51
Resistance Level
$3.59
Current Trend
Strong Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.51
Wall Street Target
$490.00
(+19040.6%)
Revenue Growth (YoY)
-22.8%
Valuation Discount vs History
-20.7% cheaper
PE vs Historical
3.5 vs 7.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-20.7%
(market-implied from PE analysis)
1-Year Target
$2.30
(-10%)
2-Year Target
$2.07
(-19%)
3-Year Target
$1.87
(-27%)
3-Yr Target (if PE normalizes)
(PE: 4→7)
$3.73
(+46%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 3.5 to 7.0
Stabilization Target:
$5.11
(+99.6%)
PE Expansion Potential:
+99.6%
Share & Embed Analysis
Last updated: October 22, 2026 1:38 AM ET
Data refreshes hourly during market hours. Next update: 2:38 AM
Data refreshes hourly during market hours. Next update: 2:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SCLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
30 analysts |
$283 | 48 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1328 | 36 SELL |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$160 | 42 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$244 | 43 HOLD |
|
MRK
Merck & Company Inc |
STRONG BUY
27 analysts |
$158 | 50 HOLD |
